Braveheart Bio, Inc. (BRVE) Financials
BRVE Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 81.9 million | 160.3 million |
| March 31, 2025 | ? | ? |
BRVE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -8.2 million | 1.8 million |
| March 31, 2025 | ? | ? |
BRVE Net Income
No data available :(
BRVE Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | - | - | 667000 |
| March 31, 2025 | - | - | - |
BRVE Shares Outstanding
BRVE Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 3.0 million | 10.9 million | 4.1 million | - |
| March 31, 2025 | - | - | 5000 | - |
BRVE Cost of Revenue
No data available :(
BRVE
Price: $19.34
52 week price:
Earnings Per Share: -1.87 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 1.4 billion